Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). METHODS: In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose of 200 mg every 3 weeks) or the investigator's choice of platinum-based chemotherapy. Crossover from the chemotherapy group to the pembrolizumab group was permitted in the event of disease progression. The primary end point, progression-free survival, was assessed by means of blinded, independent, central radiologic review. Secondary end points were overall survival, objective response rate, and safety. RESULTS: Median progression-free survival was 10.3 months (95% confidence interval [CI], 6.7 to not reached) in the pembrolizumab group versus 6.0 months (95% CI, 4.2 to 6.2) in the chemotherapy group (hazard ratio for disease progression or death, 0.50; 95% CI, 0.37 to 0.68; P<0.001). The estimated rate of overall survival at 6 months was 80.2% in the pembrolizumab group versus 72.4% in the chemotherapy group (hazard ratio for death, 0.60; 95% CI, 0.41 to 0.89; P=0.005). The response rate was higher in the pembrolizumab group than in the chemotherapy group (44.8% vs. 27.8%), the median duration of response was longer (not reached [range, 1.9+ to 14.5+ months] vs. 6.3 months [range, 2.1+ to 12.6+]), and treatment-related adverse events of any grade were less frequent (occurring in 73.4% vs. 90.0% of patients), as were grade 3, 4, or 5 treatment-related adverse events (26.6% vs. 53.3%). CONCLUSIONS: In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy. (Funded by Merck; KEYNOTE-024 ClinicalTrials.gov number, NCT02142738 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, ICIs are also associated with frequent and potentially organ- or life-threatening immune-related adverse events (irAEs), which generally mimic autoimmune or inflammatory conditions”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“indeed, up to 90% of patients treated with ipilimumab and up to 70% of those treated with PD-1/PD-L1 antibodies experience at least one irAE).3,4”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initial trials on anti-PD-1 and anti-PD-L1 inhibitors reported a significant association between pre-treatment intratumoral PD-L1 expression and response to treatment in a variety of tumor types including melanoma and NSCLC”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Reck et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Research works printed but not linked: 1
- Xiao HQ, 2016, Onco Targets Ther, 9, 1471
Cited by
Items 701–800 of 1,054
Johnson, A. M., Bullock, B. L., Neuwelt, A. J., Poczobutt, J. M., Kaspar, R. E., Li, H. Y., Kwak, J. W., Hopp, K., Weiser-Evans, M. C. M., Heasley, L. E., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900778 · Cited by 135
Immunotherapy of Neuroblastoma: Facts and Hopes
Anderson, J., Majzner, R. G., & Sondel, P. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1356 · Cited by 142
French Endocrine Society guidance on endocrine side effects of immunotherapy
Castinetti, F., Albarel, F., Archambeaud, F., Bertherat, J., Bouillet, B., Buffier, P., Briet, C., Cariou, B., Caron, P., Chabre, O., et al. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0320 · Cited by 140
Lin, J. J., Chin, E., Yeap, B. Y., Ferris, L. A., Kamesan, V., Lennes, I. T., Sequist, L. V., Heist, R. S., Mino-Kenudson, M., Gainor, J. F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.001 · Cited by 140
“Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 and its ligand programmed death ligand 1 (PD-L1) have entered the clinic across multiple solid tumors, including NSCLC.1 On the basis of KEYNOTE-189, pembrolizumab plus platinum-doublet chemotherapy is the standard first-line treatment for nonsquamo…”
Gettinger, S. N., Wurtz, A., Goldberg, S. B., Rimm, D., Schalper, K., Kaech, S., Kavathas, P., Chiang, A., Lilenbaum, R., Zelterman, D., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.008 · Cited by 135
Variant classification in precision oncology
Leichsenring, J., Horak, P., Kreutzfeldt, S., Heining, C., Christopoulos, P., Volckmar, A., Neumann, O., Kirchner, M., Ploeger, C., Budczies, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32358 · Cited by 140
Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey
Gregg, J. P., Li, T., & Yoneda, K. Y. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.04.14 · Cited by 140
Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
Moya‐Horno, I., Viteri, S., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017745012 · Cited by 139
Role of immune-checkpoint inhibitors in lung cancer
Jain, P., Jain, C., & Velcheti, V. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465817750075 · Cited by 144
Khozin, S., Miksad, R. A., Adami, J., Boyd, M., Brown, N. R., Gossai, A., Kaganman, I., Kuk, D., Rockland, J. M., Pazdur, R., et al. (2019) · Cancer · doi:10.1002/cncr.32383 · Cited by 137
Ghini, V., Laera, L., Fantechi, B., Monte, F. D., Benelli, M., McCartney, A., Tenori, L., Luchinat, C., & Pozzessere, D. (2020) · Cancers · doi:10.3390/cancers12123574 · Cited by 140
Lebow, E. S., Hubbeling, H., Yeap, B. Y., Mehan, W. A., Shaw, A. T., Oh, K. S., Gainor, J. F., & Shih, H. A. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.02.175 · Cited by 138
Chae, Y. K., Davis, A. A., Raparia, K., Agte, S., Pan, A. P., Mohindra, N. A., Villaflor, V. M., & Giles, F. J. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.09.008 · Cited by 138
Shoji, F., Takeoka, H., Kozuma, Y., Toyokawa, G., Yamazaki, K., Ichiki, M., & Takeo, S. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.08.006 · Cited by 140
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer
Suresh, S., Chen, B., Zhu, J., Golden, R. J., Lu, C., Evers, B. M., Novaresi, N., Smith, B., Zhan, X., Schmid, V., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0056-0 · Cited by 125
Zhou, C., Wang, Y., Zhao, J., Chen, G., Liu, Z., Gu, K., Huang, M., He, J., Chen, J., Ma, Z., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3136 · Cited by 138
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
Singh, N., Temin, S., Baker, S., Blanchard, E. M., Brahmer, J. R., Celano, P., Duma, N., Ellis, P. M., Elkins, I. B., Haddad, R. Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00825 · Cited by 138
Self-citationMechanisms of resistance to immune checkpoint inhibitors
Nagasaki, J., Ishino, T., & Togashi, Y. (2022) · Cancer Science · doi:10.1111/cas.15497 · Cited by 138
Prasad, V. K., & Kaestner, V. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.06.007 · Cited by 137
Nakanishi, Y., Masuda, T., Yamaguchi, K., Sakamoto, S., Horimasu, Y., Nakashima, T., Miyamoto, S., Tsutani, Y., Iwamoto, H., Fujitaka, K., et al. (2019) · Respiratory Investigation · doi:10.1016/j.resinv.2019.05.002 · Cited by 137
Roch, B., Coffy, A., Jean-Baptiste, S., Palaysi, E., Daurès, J., Pujol, J.-L., & Bommart, S. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.003 · Cited by 137
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
Aredo, J. V., Mambetsariev, I., Hellyer, J. A., Amini, A., Neal, J. W., Padda, S. K., McCoach, C. E., Riess, J. W., Cabebe, E. C., Naidoo, J., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.1628 · Cited by 137
Huang, M.-Y., Jiang, X.-M., Wang, B.-L., Sun, Y., & Lu, J.-J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107694 · Cited by 136
The Evolving Modern Management of Brain Metastasis
Fecci, P. E., Champion, C. D., Hoj, J. P., McKernan, C., Goodwin, C. R., Kirkpatrick, J. P., Anders, C. K., Pendergast, A. M., & Sampson, J. H. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1624 · Cited by 138
Simeone, J. C., Nordstrom, B. L., Patel, K., & Klein, A. B. (2019) · Future Oncology · doi:10.2217/fon-2019-0348 · Cited by 121
Reardon, D. A., Kim, T. M., Frenel, J., Simonelli, M., Lopez, J. S., Subramaniam, D. S., Siu, L. L., Wang, H., Krishnan, S., Stein, K. F., et al. (2021) · Cancer · doi:10.1002/cncr.33378 · Cited by 136
Arbour, K. C., Rizvi, H., Plodkowski, A. J., Hellmann, M. D., Knezevic, A., Heller, G., Yu, H. A., Ladanyi, M., Kris, M. G., Arcila, M. E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4023 · Cited by 126
Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment
Alturki, N. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134301 · Cited by 135
Yang, L., Yang, Y., Zhang, J., Li, M., Yang, L., Wang, X., Chen, M., Zhang, H., He, B., Wang, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01983-1 · Cited by 137
PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
Hirsch, L., Zitvogel, L., Eggermont, A. M. M., & Marabelle, A. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0294-4 · Cited by 141
Fan, Y., Zhao, J., Wang, Q., Huang, D., Li, X., Chen, J., Fang, Y., Duan, J., Zhou, C., Hu, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.002 · Cited by 135
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
Bertucci, F., & Gonçalvès, A. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0627-0 · Cited by 138
Tissue and Blood Biomarkers in Lung Cancer: A Review
Duffy, M. J., & O'Byrne, K. J. (2018) · Advances in clinical chemistry · doi:10.1016/bs.acc.2018.05.001 · Cited by 135
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
Lim, S. M., Hong, M. H., & Kim, H. R. (2020) · Immune Network · doi:10.4110/in.2020.20.e10 · Cited by 135
Le, X., Negrao, M. V., Reuben, A., Federico, L., Diao, L., McGrail, D. J., Nilsson, M. B., Robichaux, J. P., Guijarro, I., Patel, S. A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.010 · Cited by 135
Zhang, Q., Tang, L., Zhou, Y., He, W., & Li, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663986 · Cited by 136
Alzheimer's disease outlook: controversies and future directions
Frisoni, G. B., Aho, E., Brayne, C., Ciccarelli, O., Dubois, B., Fox, N. C., Frederiksen, K. S., Gabay, C., Garibotto, V., Hofmarcher, T., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01389-3 · Cited by 135
Davies, M., & Duffield, E. A. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s141577 · Cited by 128
Immunotherapy comes of age: Immune aging & checkpoint inhibitors
Elias, R., Karantanos, T., Sira, E., & Hartshorn, K. L. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.02.001 · Cited by 133
Hellmann, M. D., Jänne, P. A., Opyrchal, M., Hafez, N., Raez, L. E., Gabrilovich, D. I., Wang, F., Trepel, J. B., Lee, M.-J., Yuno, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3305 · Cited by 133
Rangachari, D., VanderLaan, P. A., Shea, M., Le, X., Huberman, M. S., Kobayashi, S. S., & Costa, D. B. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.12.026 · Cited by 133
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung Cancer
Lin, J. J., Ritterhouse, L. L., Ali, S. M., Bailey, M., Schrock, A. B., Gainor, J. F., Ferris, L. A., Mino-Kenudson, M. A., Miller, V. A., Iafrate, A. J., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.004 · Cited by 133
Guan, X., Zhang, C., Zhao, J., Sun, G., Song, Q., & Jia, W. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.012 · Cited by 133
Hellmann, M. D., Nabet, B. Y., Rizvi, H., Chaudhuri, A. A., Wells, D. K., Dunphy, M. P. S., Chabon, J. J., Liu, C. L., Hui, A. B., Arbour, K. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3418 · Cited by 125
Kong, Y., Xu, C., Cui, C., Yang, W., Yang, S., Chi, Z., Sheng, X., Si, L., Xie, Y., Yu, J., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00169-w · Cited by 136
Pisapia, P., Malapelle, U., & Troncone, G. (2018) · Acta Cytologica · doi:10.1159/000492710 · Cited by 134
Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing
Cohen, D. B., Hondelink, L. M., Solleveld‐Westerink, N., Kolkman-Uljee, S. M., Ruano, D., Cleton-Jansen, A., von der Thüsen, J. H., Ramai, S. R. S., Postmus, P. E., van Roggen, J. F. G., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.019 · Cited by 132
Özgüroğlu, M., Kılıçkap, S., Sezer, A., Gümüş, M., Bondarenko, I., Gogishvili, M., Nechaeva, M., Schenker, M., Çiçin, İ., Ho, G. F., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00329-7 · Cited by 133
Immune checkpoint inhibitors in advanced non–small cell lung cancer
Assi, H. I., Kamphorst, A. O., Moukalled, N. M., & Ramalingam, S. S. (2018) · Cancer · doi:10.1002/cncr.31105 · Cited by 121
Wei, J. S., Kuznetsov, I. B., Zhang, S., Song, Y., Asgharzadeh, S., Sindiri, S., Wen, X., Patidar, R., Najaraj, S., Walton, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0599 · Cited by 132
The clinical utility of tumor mutational burden in non-small cell lung cancer
Greillier, L., Tomasini, P., & Barlési, F. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.10.08 · Cited by 131
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 132
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors
Adib, E., Nassar, A. H., Akl, E. W., Alaiwi, S. A., Nuzzo, P. V., Mouhieddine, T. H., Sonpavde, G., Haddad, R. I., Mouw, K. W., Giannakis, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0575 · Cited by 132
Chao, H., Berman, A. T., Simone, C. B., Ciunci, C. A., Gabriel, P. E., Lin, H., Both, S., Langer, C. J., Lelionis, K., Rengan, R., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.018 · Cited by 130
Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
Bilir, C., & Sarısözen, C. (2017) · Journal of Oncological Sciences · doi:10.1016/j.jons.2017.04.001 · Cited by 130
Hersom, M., & Jørgensen, J. T. (2017) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000460 · Cited by 130
Yoneda, K., Kuwata, T., Kanayama, M., Mori, M., Kawanami, T., Yatera, K., Ohguri, T., Hisaoka, M., Nakayama, T., & Tanaka, F. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0541-3 · Cited by 130
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Yang, H., Liang, S.-Q., Schmid, R. A., & Peng, R.-W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00953 · Cited by 129
“A landmark trial (KEYNOTE-024) demonstrated that pembrolizumab was superior to chemotherapy in advanced NSCLC (potentially including patients with KRAS-mutations), among which more than 50% had high PD-L1 expression (95).”
BackgroundMolecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009619666181210114559 · Cited by 130
Cherny, N. I., de Vries, E. G. E., Dafni, U. G., Garrett-Mayer, E. S., McKernin, S. E., Piccart, M. J., Latino, N. J., Douillard, J.-Y., Schnipper, L. E., Somerfield, M. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00729 · Cited by 130
The Prognostic and Therapeutic Value of PD-L1 in Glioma
Chen, R. Q., Liu, F., Qiu, X. Y., & Chen, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01503 · Cited by 131
Khan, M., Lin, J., Liao, G., Tian, Y., Liang, Y., Li, R., Liu, M., & Yuan, Y. (2018) · Medicine · doi:10.1097/md.0000000000011936 · Cited by 107
Tumor Vasculatures: A New Target for Cancer Immunotherapy
Liu, Z., Wang, Y., Huang, Y., Kim, B. Y. S., Shan, H., Wu, D., & Jiang, W. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.001 · Cited by 129
Li, M., Spakowicz, D. J., Burkart, J. T., Patel, S. P., Husain, M., He, K., Bertino, E. M., Shields, P. G., Carbone, D. P., Verschraegen, C. F., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02982-4 · Cited by 129
Zhang, H., Liu, Z., Wen, H., Guo, Y., Xu, F., Zhu, Q., Yuan, W., Luo, R., Lu, C., Liu, R., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03173-w · Cited by 130
Liu, X., Tang, R., Xu, J., Tan, Z., Liang, C., Meng, Q., Lei, Y., Hua, J., Zhang, Y., Liu, J., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-329349 · Cited by 129
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Liu, B., Song, Y., & Liu, D. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0541-9 · Cited by 121
Zhang, K., Hong, X., Song, Z., Xu, Y., Li, C., Wang, G., Zhang, Y., Zhao, X., Zhao, Z., Zhao, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3976 · Cited by 129
Thompson, J. C., Davis, C. W., Deshpande, C. G., Hwang, W., Jeffries, S., Huang, A. C. C., Mitchell, T. C., Langer, C. J., & Albelda, S. Μ. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000974 · Cited by 129
Mollaei, M., Hassan, Z. M., Khorshidi, F., & Langroudi, L. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101056 · Cited by 131
Queirolo, P., & Spagnolo, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.002 · Cited by 129
Gatalica, Z., Xiu, J., Swensen, J. J., & Vranić, S. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.021 · Cited by 127
Lazzari, C., Karachaliou, N., Bulotta, A., Viganó, M., Mirabile, A., Brioschi, E., Santarpia, M., Gianni, L., Rosell, R., & Gregorc, V. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918762094 · Cited by 117
Hofman, P. M., Badoual, C., Henderson, F., Berland, L., Hamila, M., Long-Mira, É., Lassalle, S., Roussel, H., Hofman, V., Tartour, É., et al. (2019) · Cancers · doi:10.3390/cancers11030283 · Cited by 127
Kotecha, R. R., Kim, J. M., Miller, J. A., Juloori, A., Chao, S. T., Murphy, E. S., Peereboom, D. M., Mohammadi, A. M., Barnett, G. H., Vogelbaum, M. A., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz046 · Cited by 127
Voong, K. R., Hazell, S. Z., Fu, W., Hu, C., Lin, C. T., Ding, K., Suresh, K. S., Hayman, J., Hales, R. K., Alfaifi, S. A., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.02.018 · Cited by 127
Self-citationGriguolo, G., Pascual, T., Dieci, M. V., Guarneri, V., & Prat, A. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0548-6 · Cited by 127
Wang, C., Qiao, W., Jiang, Y., Zhu, M., Shao, J., Wang, T., Liu, D., & Li, W. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29371 · Cited by 127
Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights
Meador, C. B., & Hata, A. N. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107522 · Cited by 127
Joung, J., Kirchgatterer, P. C., Singh, A., Cho, J. H., Nety, S. P., Larson, R. C., Macrae, R. K., Deasy, R., Tseng, Y., Maus, M. V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29205-8 · Cited by 128
Leprieur, E. G., Duménil, C., Julié, C., Giraud, V., Dumoulin, J., Labrune, S., & Chinet, T. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.041 · Cited by 126
Negrao, M. V., Lam, V. K., Reuben, A., Rubin, M. L., Landry, L. L., Roarty, E. B., Rinsurongkawong, W., Lewis, J., Roth, J. A., Swisher, S. G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.008 · Cited by 112
The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma
Hong, S., Liu, D., Luo, S., Fang, W., Zhan, J., Fu, S., Zhang, Y., Wu, X., Zhou, H., Chen, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10902-w · Cited by 126
Montasser, A., Bèaufrere, A., Cauchy, F., Bouattour, M., Soubrane, O., Albuquerque, M., & Paradis, V. (2020) · Histopathology · doi:10.1111/his.14317 · Cited by 126
Tong, H., Sun, J., Fang, J., Zhang, M., Liu, H., Xia, R., Zhou, W., Liu, K., & Chen, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859323 · Cited by 126
Cho, B. C., Lee, J. S., Wu, Y.-L. L. C., Çiçin, İ., Cobo, M., Ahn, M., Cuppens, K., Veillon, R., Nadal, E., Dias, J. M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.08.018 · Cited by 126
Self-citationKim, J. H., Kim, H. S., & Kim, B. J. (2017) · Oncotarget · doi:10.18632/oncotarget.17594 · Cited by 115
Ritchie, G., Gasper, H., Man, J., Lord, S., Marschner, I., Friedlander, M., & Lee, C. K. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5236 · Cited by 122
Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody
Li, D., Cheng, S., Zou, S., Zhu, D., Zhu, T., Wang, P., & Zhu, X. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00062 · Cited by 125
Grassadonia, A., Sperduti, I., Vici, P., Iezzi, L., Brocco, D., Gamucci, T., Pizzuti, L., Maugeri‐Saccà, M., Marchetti, P., Cognetti, G., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120542 · Cited by 126
Alborelli, I., Leonards, K., Rothschild, S. I., Leuenberger, L. P., Prince, S. S., Mertz, K. D., Poechtrager, S., Buess, M., Zippelius, A., Laubli, H. P., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5344 · Cited by 125
Gainor, J. F., Rizvi, H., Jimenez Aguilar, E., Skoulidis, F., Yeap, B. Y., Naidoo, J., Khosrowjerdi, S., Mooradian, M., Lydon, C., Illei, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.015 · Cited by 115
The current treatment landscape in the UK for stage III NSCLC
Limited, O. B. O. A. U., & Evison, M. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01069-z · Cited by 126
Zhou, G., Lieshout, R., van Tienderen, G. S., de Ruiter, V., van Royen, M. E., Boor, P. P. C., Magré, L., Desai, J., Köten, K., Kan, Y. Y., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01839-x · Cited by 109
Clinical pharmacology considerations for the development of immune checkpoint inhibitors
Sheng, J., Srivastava, S., Sanghavi, K., Lu, Z., Schmidt, B. J., Bello, A., & Gupta, M. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.990 · Cited by 124
Ferrara, R., Imbimbo, M., Malouf, R. S., Paget‐Bailly, S., Calais, F., Marchal, C., & Westeel, V. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013257.pub3 · Cited by 124
Yang, Y., Li, L., Jiang, Z., Wang, B., & Pan, Z. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02641-5 · Cited by 124
You, B., Bolze, P., Lotz, J., Massardier, J., Gladieff, L., Joly, F., Hajri, T., Maucort‐Boulch, D., Bin, S., Rousset, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00803 · Cited by 124
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
Di Federico, A., De Giglio, A., Parisi, C., & Gelsomino, F. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.011 · Cited by 105
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
Pansy, K., Uhl, B., Krstić, J., Szmyra, M., Fechter, K., Santiso, A., Thüminger, L., Greinix, H., Kargl, J., Prochazka, K. T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413311 · Cited by 124
Metadata
- Authors
- Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Leiby, M. A., Lubiniecki, G. M., Shentu, Y., Rangwala, R., & Brahmer, J. R.
- Affiliations
- The University of Sydney (AU)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-10
- Volume
- 375
- Issue
- 19
- Pages
- 1823-1833
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2527905628
- Cited by
- 10,089
- References
- 54
- Citations by year
- 2026: 584 · 2025: 750 · 2024: 913 · 2023: 1012 · 2022: 1108 · 2021: 1321 · 2020: 1324 · 2019: 1154 · 2018: 1132 · 2017: 724 · 2016: 46
- FWCI
- 548.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- pembrolizumab, PD-L1-positive non-small cell lung cancer, PD-1 inhibitors, immune checkpoint inhibitors, platinum-based chemotherapy, progression-free survival, overall survival, objective response rate, treatment-related adverse events, EGFR wild-type, immunotherapy versus chemotherapy, duration of response
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, Platinum Compounds, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.